# Stratified signaling network remodeling of kinase–transcription factors’ interactions in Parkinson’s disease

**Authors:** Xiaoyan Zhou, Luca Parisi, Sicen Liu, Ziqi Cheng, Hanwen Liang, Mansour Youseffi, Farideh Javid, Renfei Ma

PMC · DOI: 10.1093/bioadv/vbag059 · Bioinformatics Advances · 2026-02-17

## TL;DR

This paper introduces a new computational framework to study how signaling networks involving kinases and transcription factors change in different subgroups of Parkinson’s disease.

## Contribution

The novel stratified framework integrates gene expression, inferred transcription factor activity, and kinase interaction data to reveal subgroup-specific signaling features in Parkinson’s disease.

## Key findings

- A recurring pattern of STAT family activation downstream of tyrosine kinases was observed across multiple PD subgroups.
- PD_LRRK2 showed unique involvement of immune-metabolic pathways like AMPK to HNF4A and PAK5 to NF-κB.
- Stress and apoptosis mechanisms involving MAPK10, TP53, and hormone receptors were prominent in PD_GBA and prodromal cohorts.

## Abstract

Understanding how signaling networks differ across molecular subgroups of Parkinson’s disease (PD) is essential for gaining further mechanistic insights and advancing therapeutic development for the disease. This study introduces an integrative, stratified computational framework to characterize subgroup-specific changes in kinase–transcription factors’ (TFs) interactions using transcriptomic profiles.

Differential expression analysis was leveraged to identify kinases with altered expression across various PD subgroups, while transcription factor activity inferred by multi-sample Virtual Inference of Protein-activity by Enriched Regulon revealed dysregulated transcription relative to controls. Phosphorylation data from SIGNOR 4.0 enabled the construction of kinase–TF subnetworks, which were analysed via pathway enrichment to reveal affected biological pathways. Comparative analyses and modeling revealed both shared and distinct signaling features among PD stratified subgroups. A recurring pattern across multiple groups involved STAT family-specific activation downstream of receptor and non-receptor tyrosine kinases, consistently with a conserved inflammatory and pro-survival signaling axis. In contrast, PD_LRRK2 showed selective involvement of immune-metabolic pathways, including AMPK to HNF4A and PAK5 to NF-κB, while PD_GBA and prodromal cohorts were characterized by stress and apoptosis-related mechanisms involving MAPK10 (JNK3), TP53, and hormone receptor pathways (AR and ESR1). Overall, this novel stratified computational framework integrates gene expression, infers subtle TF activity, identifies differentially expressed kinases, and leverages mechanistic interaction data to unveil signaling heterogeneity in PD. Identifying regulators and subgroup-specific network features provides opportunities to inform, influence, and enable the unveiling of novel biomarkers and develop more effective and proactive precision therapeutics.

Source code is available at https://github.com/xyzhou218/Kin_TF_net.

## Linked entities

- **Genes:** SOAT1 (sterol O-acyltransferase 1) [NCBI Gene 6646], PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562], HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172], PAK5 (p21 (RAC1) activated kinase 5) [NCBI Gene 57144], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], MAPK10 (mitogen-activated protein kinase 10) [NCBI Gene 5602], TP53 (tumor protein p53) [NCBI Gene 7157], AR (androgen receptor) [NCBI Gene 367], ESR1 (estrogen receptor 1) [NCBI Gene 2099]
- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** NTRK3 (neurotrophic receptor tyrosine kinase 3) [NCBI Gene 4916] {aka GP145-TrkC, TRKC, gp145(trkC)}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, HNF4A (hepatocyte nuclear factor 4 alpha) [NCBI Gene 3172] {aka FRTS4, HNF4, HNF4a7, HNF4a8, HNF4a9, HNF4alpha}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, TFEB (transcription factor EB) [NCBI Gene 7942] {aka ALPHATFEB, BHLHE35, TCFEB}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, PRKCD (protein kinase C delta) [NCBI Gene 5580] {aka ALPS3, CVID9, MAY1, PKCD, nPKC-delta}, PAK5 (p21 (RAC1) activated kinase 5) [NCBI Gene 57144] {aka PAK7}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, PBK (PDZ binding kinase) [NCBI Gene 55872] {aka CT84, HEL164, Nori-3, SPK, TOPK}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, PRKN (parkin RBR E3 ubiquitin protein ligase) [NCBI Gene 5071] {aka AR-JP, LPRS2, PARK2, PDJ}, JAK3 (Janus kinase 3) [NCBI Gene 3718] {aka JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK}, GBA1 (glucosylceramidase beta 1) [NCBI Gene 2629] {aka GBA, GCB, GLUC}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, MAPK10 (mitogen-activated protein kinase 10) [NCBI Gene 5602] {aka JNK3, JNK3A, PRKM10, SAPK1b, p493F12, p54bSAPK}, AURKB (aurora kinase B) [NCBI Gene 9212] {aka AIK2, AIM-1, AIM1, ARK-2, ARK2, AurB}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, CAMK2A (calcium/calmodulin dependent protein kinase II alpha) [NCBI Gene 815] {aka CAMKA, CaMKIINalpha, CaMKIIalpha, MRD53, MRT63}, ETS2 (ETS proto-oncogene 2, transcription factor) [NCBI Gene 2114] {aka ETS2IT1}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, LRRK2 (leucine rich repeat kinase 2) [NCBI Gene 120892] {aka AURA17, DARDARIN, PARK8, RIPK7, ROCO2}, TNK2 (tyrosine kinase non receptor 2) [NCBI Gene 10188] {aka ACK, ACK-1, ACK1, p21cdc42Hs}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) [NCBI Gene 5562] {aka AMPK, AMPK alpha 1, AMPKa1}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, TTK (TTK protein kinase) [NCBI Gene 7272] {aka CT96, ESK, MPH1, MPS1, MPS1L1, PYT}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, EPHA3 (EPH receptor A3) [NCBI Gene 2042] {aka EK4, ETK, ETK1, HEK, HEK4, TYRO4}, SLC6A3 (solute carrier family 6 member 3) [NCBI Gene 6531] {aka DAT, DAT1, PKDYS, PKDYS1}, SPI1 (Spi-1 proto-oncogene) [NCBI Gene 6688] {aka AGM10, OF, PU.1, SFPI1, SPI-1, SPI-A}
- **Diseases:** synaptic impairment (MESH:D012183), impaired olfactory function (MESH:D000857), Dopaminergic Deficit (MESH:D009461), stroke (MESH:D020521), tumorigenesis (MESH:D063646), SWEDD (MESH:D004401), multiple system atrophy (MESH:D019578), central nervous system (CNS) disorders (MESH:D002493), neuroinflammation (MESH:D000090862), lysosomal dysfunction (MESH:D016464), cancer (MESH:D009369), Alzheimer's disease (MESH:D000544), PD (MESH:D010300), mitochondrial dysfunction (MESH:D028361), neurodegeneration (MESH:D019636), inflammation (MESH:D007249), RBD (MESH:D020187), synaptic dysfunction (MESH:C536122), Prodromal_hyposmia (MESH:D062706), MS (MESH:D009103), dementia (MESH:D003704), depression (MESH:D003866), neuronal death (MESH:D009410), Hyposmia (MESH:D000086582), leukemic (MESH:D007938), metastasis (MESH:D009362), neuro-inflammatory (MESH:C536203)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12955839/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12955839/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12955839/full.md

---
Source: https://tomesphere.com/paper/PMC12955839